CG
CHRS icon

Cutler Group’s Coherus Oncology CHRS Stock Holding History

Cutler Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,000
Closed -$4K – 3843
2023
Q2 		$4K Buy
+4,000
New +$23.6K ﹤0.01% 2689
2018
Q1 		– Sell
-1,200
Closed -$5K – 4520
2017
Q4 		$5K Sell
1,200
-9,200
-88% -$98.5K ﹤0.01% 3592
2017
Q3 		$46K Sell
10,400
-3,200
-24% -$42.3K ﹤0.01% 2311
2017
Q2 		$55K Buy
13,600
+7,500
+123% +$144K ﹤0.01% 2395
2017
Q1 		$51K Sell
6,100
-28,900
-83% -$711K ﹤0.01% 2384
2016
Q4 		$55K Buy
35,000
+3,600
+11% +$101K ﹤0.01% 2436
2016
Q3 		$102K Buy
31,400
+28,400
+947% +$775K ﹤0.01% 1785
2016
Q2 		$8K Buy
+3,000
New +$56.3K ﹤0.01% 4393

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Cutler Group's CHRS Position: Q3 2023 in Review

Cutler Group sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 2,000 shares — an estimated $8K sold.

Cutler Group first reported a position in CHRS in Q3 2016 and held it in 12 quarters. The position peaked at $211K in Q4 2016. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • Cutler Group reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • Cutler Group sold 2,000 Coherus Oncology shares in Q3 2023, an estimated $8K.
  • Cutler Group first reported a position in Coherus Oncology in Q3 2016 and held it in 12 quarters.
  • Cutler Group's Coherus Oncology position peaked at $211K in Q4 2016.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.